Advertisement
AMRN vs MGNX
Which Stock Would AI Choose? Amarin Corporation (AMRN) vs. MacroGenics (MGNX) Stock Comparison
Key Takeaways
- AMRN and MGNX operate in different segments of the biopharmaceutical industry — cardiovascular health versus immuno-oncology — creating distinct risk/reward profiles.
- Revenue generation separates the two: AMRN has a commercialized product generating recurring sales, while MGNX remains largely reliant on collaboration revenue and pipeline advances.
- Recent market activity shows both stocks trading well below their historical highs, with macro pressures and company-specific headwinds weighing on sentiment.
- Risk tolerance is the defining factor: AMRN offers lower volatility tied to prescription trends, while MGNX carries binary-event risk linked to clinical trial outcomes.
- Tickeron's AI trading bots provide a data-driven lens for evaluating setups in both tickers, adjusting dynamically to shifting market conditions.
Introduction
Biopharmaceutical stocks often attract investors seeking asymmetric upside, but not all drug developers are created equal. This comparison examines Amarin Corporation (AMRN) and MacroGenics (MGNX) — two companies at different stages of the commercialization and development lifecycle. AMRN markets a cardiovascular drug with an established revenue base, while MGNX is advancing a pipeline of antibody-based cancer therapies through clinical trials. For traders evaluating biotech exposure, understanding the operational and market contrasts between these two names is essential. This analysis covers recent performance, business positioning, and how AI-driven tools assess the opportunity set in each stock.
AMRN Overview and Recent Performance
Amarin Corporation is a pharmaceutical company focused on cardiovascular health, best known for its flagship product Vascepa (icosapent ethyl), a prescription-grade omega-3 fatty acid approved to reduce cardiovascular risk in certain patient populations. While Vascepa achieved blockbuster status in the U.S. several years ago, the company has faced intensifying generic competition following the expiration of key patents. In recent weeks, AMRN's share price has reflected ongoing investor concerns around revenue erosion and the pace of its European market expansion.
Over recent market activity, AMRN has traded in a relatively tight but downward-biased range, with volume patterns suggesting subdued institutional interest. The company continues to pursue international growth opportunities and cost-management initiatives, but the overhang of generic entrants in the U.S. market has kept sentiment cautious. Price action indicates a stock searching for a catalyst — one that has not yet materialized in a meaningful way. Investors have been monitoring prescription data and quarterly revenue trends closely, as these remain the primary drivers of near-term valuation.
MGNX Overview and Recent Performance
MacroGenics is a biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer. Its portfolio includes both wholly owned and partnered programs, with a focus on immuno-oncology targets. The company generates revenue primarily through collaboration agreements with larger pharmaceutical partners, rather than from direct product sales, which means its financial profile is shaped heavily by milestone payments and licensing activity.
In recent weeks, MGNX shares have experienced elevated volatility, a characteristic common among early-to-mid-stage biotech developers. Market participants have been reacting to clinical data readouts, pipeline updates, and broader shifts in sentiment toward the biotech sector. The stock has faced downward pressure amid risk-off positioning in speculative growth names, though periodic spikes in trading volume suggest that traders remain attuned to potential catalysts. With no approved in-house product generating recurring revenue, MGNX's valuation hinges on clinical trial progress, regulatory milestones, and partnership announcements — each carrying binary risk. The company's cash runway and spending patterns have also drawn scrutiny during recent quarterly filings.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI-powered trading bots. With hundreds of bots actively trading thousands of tickers across equities, ETFs, and cryptocurrencies, only those demonstrating the strongest alignment with current market conditions earn a spot in this featured section. These bots deploy diverse strategies — ranging from swing trading and trend following to mean reversion and breakout models — each with distinct timeframes, win rates, and historical performance metrics. Some bots in the ecosystem have recorded annualized returns exceeding 50%, while others prioritize consistency with lower drawdowns. Whether focused on biotech names like AMRN and MGNX or spanning multiple sectors, Tickeron's bots adapt algorithmically to evolving market regimes. Explore the Trending AI Robots to discover which strategies are currently signaling opportunity.
Head-to-Head Comparison
From a business model perspective, the contrast is sharp. AMRN is a commercial-stage company with an established product and recurring revenue, albeit under threat from generic competition. MGNX is preclinical-to-clinical, generating income mainly from collaborations and milestone payments rather than product sales. This fundamental difference shapes their respective risk profiles: AMRN faces execution risk tied to international market penetration and cost discipline, while MGNX carries binary clinical risk — a single trial failure could materially alter its trajectory.
On growth drivers, AMRN's upside depends largely on ex-U.S. adoption of Vascepa and potential label expansions, though the pathway has narrowed. MGNX's growth prospects are tied to its immuno-oncology pipeline and the ability to advance candidates toward regulatory submissions. Sector exposure also diverges: AMRN sits in the cardiovascular therapeutic area, which tends to be less sentiment-driven than oncology, where MGNX operates amid fiercer competition but also greater potential for transformational gains.
Market sentiment for both stocks remains fragile. AMRN is viewed as a value-trap candidate by some and a turnaround play by others. MGNX is perceived as a high-upside, high-risk biotech that will live and die by its data. Recent momentum has been unfavorable for both, reflecting broader risk-off flows in the small-to-mid-cap biotech space. Investors weighing these names must decide between a revenue-generating but challenged commercial story and a speculative development-stage pipeline with binary outcomes.
Tickeron AI Verdict
Based on observable market data and trend characteristics, Tickeron's AI framework would likely favor AMRN in the current environment — primarily due to its more established revenue base and comparatively lower volatility profile. While neither stock exhibits a strong bullish trend pattern at this juncture, AMRN's relative stability and predictable earnings structure offer a more favorable backdrop for algorithmic trend-following and mean-reversion strategies. MGNX, by contrast, presents a higher-risk proposition where AI models would require clear momentum confirmation or a defined catalyst before signaling entry. In probabilistic terms, AMRN currently offers a steadier, albeit modest, setup, whereas MGNX remains a higher-beta name that could generate outsized returns — or losses — depending on clinical events. Traders should monitor the evolving signals from Tickeron's bots for real-time shifts in conviction across both tickers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Buy and MGNX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 0 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).
- AMRN’s FA Score: 0 green, 5 red.
- MGNX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 6 TA indicator(s) are bullish while MGNX’s TA Score has 2 bullish TA indicator(s).
- AMRN’s TA Score: 6 bullish, 4 bearish.
- MGNX’s TA Score: 2 bullish, 7 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а +5.24% price change this week, while MGNX (@Biotechnology) price change was -0.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.
Reported Earning Dates
MGNX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-1.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AMRN | MGNX | AMRN / MGNX | |
| Capitalization | 299M | 235M | 127% |
| EBITDA | -43.2M | -50.64M | 85% |
| Gain YTD | 2.186 | 129.193 | 2% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 186M | 157M | 118% |
| Total Cash | 315M | 154M | 205% |
| Total Debt | 5.26M | 36.5M | 14% |
AMRN | MGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 99 | |
PRICE GROWTH RATING 1..100 | 61 | 37 | |
P/E GROWTH RATING 1..100 | 100 | 95 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (77) in the Pharmaceuticals Other industry is in the same range as MGNX (90) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MGNX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as MGNX (99) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's Price Growth Rating (37) in the Biotechnology industry is in the same range as AMRN (61) in the Pharmaceuticals Other industry. This means that MGNX’s stock grew similarly to AMRN’s over the last 12 months.
MGNX's P/E Growth Rating (95) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that MGNX’s stock grew similarly to AMRN’s over the last 12 months.
| AMRN | MGNX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 74% | 4 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 76% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 74% | 4 days ago 83% |
| MACD ODDS (%) | 4 days ago 69% | 4 days ago 89% |
| TrendWeek ODDS (%) | 4 days ago 75% | 4 days ago 87% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 89% |
| Advances ODDS (%) | 4 days ago 73% | N/A |
| Declines ODDS (%) | 11 days ago 86% | 6 days ago 85% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 84% | 4 days ago 90% |
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +0.21% | ||
| CNTB - AMRN | 55% Loosely correlated | -3.35% | ||
| HRTX - AMRN | 44% Loosely correlated | -0.24% | ||
| MGNX - AMRN | 44% Loosely correlated | -2.38% | ||
| ALXO - AMRN | 43% Loosely correlated | -0.51% | ||
| ARWR - AMRN | 40% Loosely correlated | -3.06% | ||
More | ||||